• 1
    Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998; 19(Suppl A): A53A61.
  • 2
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 13011307.
  • 3
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 16151622.
  • 4
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13831389.
  • 5
    Sacks RF, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 10011009.
  • 6
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 13491357.
  • 7
    Beisiegel U. Lipoprotein metabolism. Eur Heart J 1998; 19(Suppl A): A20A23.
  • 8
    Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998; 82: 3J10J.
  • 9
    Witztum JL. Drugs used in the treatment of hyperdyslipidemias. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th edn, eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York: McGraw-Hill International Book Co, 1996; 875897.
  • 10
    Blum CB. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: (Suppl): 3D-11D.
  • 11
    Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678682.
  • 12
    Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53: 828847.
  • 13
    Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health-Syst Pharm 1998; 55: 22532267.
  • 14
    Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65: 13291337.
  • 15
    Tikkanen MJ. Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996; 7: 385388.
  • 16
    Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 14341503.
  • 17
    Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 30153023.
  • 18
    Schectman G, Hiatt J. Dose–response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996; 125: 9901000.
  • 19
    Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease factors limiting achievement of lipid goals. Am J Med 1996; 100: 197204.
  • 20
    Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157163.
  • 21
    Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 17481754.
  • 22
    Ezzet F, Krishna G, Wexler D, Statkevich P, Kosoglou T, Batra V. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23: 871885.
  • 23
    Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in subjects with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 12091230.
  • 24
    Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis Suppl 2001; 2: 38 (Abstract).
  • 25
    Ernst ND, Cleeman J, Mullis R, Sooter-Bochenek J, Van Horn L. The National Cholesterol Education Program: implications for dietetic practitioners from the Adult Treatment Panel recommendations. J Am Diet Ass 1988; 88: 14011408.
  • 26
    Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605610.
  • 27
    Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeting to most appropriate patients. Clin Pharmacol Ther 2000; 67: 438441.
  • 28
    Gotto A, Pownall H. Manual of Lipid Disorders, 2nd edn. Baltimore: Williams & Wilkins, 1999; 292295.
  • 29
    National Institutes of Health. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 13291445.
  • 30
    Davis HR, Van Heek M, Watkins RW, et al. The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors. Drugs Affecting Lipid Metabolism (DALM); Houston, TX; January 2001 (Abstract).
  • 31
    Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with HMG-CoA reductase inhibitors in dogs. Metabolism 2001; 50: 12341241.
  • 32
    Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, Inc., 1982; 409417.
  • 33
    Kratz A, Lewandrowski KB. Normal reference laboratory values. N Engl J Med 1998; 339: 10631072.
  • 34
    Plosker GL, McTavish D, Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 1995; 50: 334363.
  • 35
    Tuomilehta J, Guimaraes AC, Kettner H, et al. Dose–response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol 1994; 24: 941949.
  • 36
    Mölgaard J, Lundh BL, Van Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis 1991; 91: S21S28.
  • 37
    Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332341.
  • 38
    Kantola T, Kivistö KT, Neuvonen PT. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177182.
  • 39
    Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84: 811815.
  • 40
    Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin Pharmacol Ther 2000; 67: 152 (Abstract).
  • 41
    Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokin 1993; 24: 195202.
  • 42
    Zhu Y, Statkevich P, Maxwell SE, et al. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor. AAPS Pharm Sci Supplement 1999; 1: S24 (Abstract).
  • 43
    Zhu Y, Statkevich P, Schuessler D, et al. Pharmacokinetics of ezetimibe in rats, dogs, and humans. AAPS Pharm Sci Supplement 2000; 2: 2660 (Abstract).
  • 44
    Kosoglou T, Kakkar T, Statkevich P, et al. Multiple-dose safety and pharmacokinetics of ezetimibe in adolescent children. Clin Pharmacol Ther 2001; 69: P52 (Abstract).
  • 45
    Krishna G, Kosoglou T, Ezzet F, et al. Effect of cimetidine on the pharmacokinetics of ezetimibe. AAPS Pharm Sci Supplement 2001; 3: [Electronic (Abstract)].
  • 46
    Lipka LJ, Knopp RH, Gitter H, et al. Ezetimibe significantly lowers low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Eur Heart J 2001; 22(Suppl): 252 (Abstract).
  • 47
    Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001; 37(Suppl A): 229A (Abstract).
  • 48
    Kosoglou T, Guillaume M, Sun S, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis Suppl 2001; 2 (2): 38 (Abstract).
  • 49
    Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between cerivastatin and the selective cholesterol absorption inhibitor ezetimibe. Eur Heart J 2001; 22(Suppl): 252 (Abstract).
  • 50
    Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects (44564E). Proc Soc Exp Biol Med 2000; 225: 191199.